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Background: Surgery is entering a new phase with the revolution in genomic technology. Cheap, mass
access to next-generation sequencing is now allowing the analysis of entire human genomes at the DNA
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underlie common surgical diseases, and enable them to be stratified for patient benefit.
Methods: This article reviews the recent developments in the molecular biology of colorectal, oesopha-
gogastric and breast cancer.
Results: The review specifically covers developments in genetic predisposition, next-generation
sequencing studies, biomarkers for stratification, prognosis and treatment, and other ’omics technologies
such as metabolomics and proteomics.
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Introduction
The field of molecular biology has undergone rapid
advancement in the past 5 years, with exciting conse-
quences for the diagnosis, treatment and follow-up of
surgical patients.
A series of enabling technologies and projects have
expanded the knowledge of how basic molecular biol-
ogy can assist in the management of surgical disease.
The first, and most important, was the Human Genome
Project, established in 1990 by the US National Insti-
tutes of Health and the UK Sanger Centre1. This
established the reference human genome by carrying
out sequencing of multiple fragments of a reference
human genome using the dye-terminator technique
described by Sanger and colleagues2. A consequence of
this technology is that the project took 10 years to pro-
duce a single genome and cost over US $3 billion to
complete.
The development of microarray technology and
next-generation sequencing (NGS) within the past 5 years
has led to a step-change in the implementation of genomic
technologies; before this, the bulk of genetic research was
carried out on DNA microarrays.
Genome-wide association studies
DNA microarrays are available from a variety of
manufacturers (Illumina, Affymetrix and Agilent) and
consist of silicon or glass slides with oligonucleotides
complementary to the DNA sequence being studied,
which are annealed to their surface. This allows cheap,
mass production of microarrays that can be used for large
population-based studies. Typically these microarrays
have between 500 000 and 1⋅5 million genomic mark-
ers, usually single-nucleotide polymorphisms (SNPs).
SNPs are single-nucleotide changes within a gene that
lead to protein change and subsequent change in the
function of that gene. When scanned with a laser,
each individual oligonucleotide fluoresces a specific
colour, depending on the bound oligonucleotide fragment
(Figs 1 and 2).
A variety of projects have been undertaken using
DNA microarrays, typically taking the form of the
genome-wide association study (GWAS). These are
usually case–control studies with cases enriched for the
disease of interest. SNPs of interest are identified and
taken forward to validation in larger cohorts, giving
insights into the disease process being studied. Examples
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Fig. 1 Image of scanned oligonucleotide array (from Wikimedia
Commons)
of GWASs include the COGENT (COlorectal cancer
GENeTics) Consortium, and the Wellcome Trust Case
Control Consortium 1/2 (WTCCC 1/2) examining
colorectal cancer, Crohn’s disease, diabetes, ischaemic
heart disease, and several other common diseases and
pathologies.
Next-generation sequencing
The most widely used NGS technology, sequencing by
synthesis (Illumina, San Diego, California, USA) allows
entire human genomes to be sequenced within 24 h at
low cost, with the sub $1000 genome barrier (X-prize)
being achieved earlier this year. Other innovative tech-
nologies include single molecular real-time sequencing
(PacBio® SMRT™; Pacific Biosciences, Menlo Park, Cal-
ifornia, USA), semiconductor sequencing (Ion Torrent™;
Life Technologies, Paisley, UK) and nanopore sequenc-
ing (Oxford Nanopore, Oxford, UK). Until recently,
NGS was limited to small studies on a few samples
owing to cost constraints, but because of the rapid fall
in price-per-sample (Fig. 3), large studies are now in
progress. The Cancer Genome Atlas (TCGA) project
is sequencing the cancer genome of 33 different cancer
types in the US population; the 100 000 Genomes Project
in the UK is undertaking to sequence 50 000 cancer
genomes and 50 000 rare disease genomes over the next
5 years.
Fig. 2 Affymetrix microarray chip fromWikimedia Commons
To carry out NGS, an inherently massively parallel tech-
nique, several steps are required. All technologies require
capture of DNA or RNA into sequencing libraries. Illu-
mina Solexa™ then uses this captured DNA/RNA to gen-
erate clusters, which are amplified. Cluster amplification
is the process whereby target DNA is immobilized on
to spatially separated template sites, allowing sequencing
reactions to occur in parallel. Sequencing is then carried
out on the clusters present on the glass slide. The slide is
portioned into eight channels, enabling independent sam-
ples to be run simultaneously. Typically, reads of between
75 and 100 base pairs are possible, and the nucleotide incor-
poration cycle is repeated until sufficient depth is covered
for all targeted regions. Data generated are then aligned
with a reference sequence, and variants are called after
comparing the sequencing data to a reference. This allows
a tumour specimen to be compared with its paired normal
tissue sample.
A critical difference in analysis of human cancers is the
concept of germline and somatic mutations. Germline
mutations are the constitutive DNA that the patient is
born with, and variation within the germline confers an
increased (or decreased) risk of cancer. Somatic mutations
occur as a consequence of tumour development, although
they may initiate tumour development by occurring
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Fig. 3 Cost in US dollars per genome sequenced in 2001–2014, at 5-month intervals (data from http://www.genome.gov/
sequencingcosts/)
spontaneously as a result of external factors such as
ionizing radiation or carcinogens.
Microarray and sequencing technologies also allow
analysis of other types of genetic information, such as
DNA methylation (epigenetics), which acts as a switch
in the regulation of gene expression. NGS also allows
analysis of gene expression by NGS of mRNA (RNA-seq)
and other genetic modifications, such as sequencing
of chromatin-immunoprecipitated DNA (ChIP-seq).
Non-coding small RNAs that may affect gene function,
such as long non-coding RNA (lncRNA), small interfering
RNA (siRNA) and small nucleolar RNA (snoRNA), can
also be analysed by NGS.
Other ’omics technologies
Other technologies are emerging as potential methods for
the downstream analysis and stratification of patient sam-
ples in surgical disease. Two examples of these technolo-
gies are metabolomics and proteomics. Metabolomics uses
either nuclear magnetic resonance or mass spectrometry
to ascertain the presence of metabolites in surgical speci-
mens. The patterns and relative abundances of the metabo-
lites observed can give clues as to the underlying biological
processes at work in the tissues studied3.
Proteomics uses mass spectrometry to understand the
structure of proteins. Several methods exist to allow
proteins to be studied in the ionized form without
fragmentation or damage including matrix-assisted
laser desorption ionization (MALDI)4 and electrospray
ionization5. Because proteins are modified after they are
produced by transcription (post-translational modifica-
tion), study of both the protein and RNA involved in
tissues allows a fuller appreciation of the changes that may
be occurring in a particular disease.
These technologies have allowed advances in under-
standing of the initiation and progression of multiple
surgical diseases, and in adjuvant therapies for surgical
disease such as chemotherapy and radiotherapy. They
also allow the possibility of population screening of
asymptomatic carriers.
Lower gastrointestinal tract: colorectal cancer
and inﬂammatory bowel disease
Genetic predisposition
The predominant surgically relevant disease types stud-
ied in the lower gastrointestinal (GI) tract have been col-
orectal cancer, Crohn’s disease and ulcerative colitis. The
COGENTConsortium6 has undertaken multiple GWASs
of patients with colorectal cancer associated with a strong
family history or extreme phenotype (such as young age of
onset), identifying ten SNPs associated with colorectal can-
cer at population-wide significance. Although inheritance
of one disease association SNP confers a population risk of
odds ratio approximately 1⋅05 (Table 1, taken from Tenesa
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Table 1 Frequency of identified single-nucleotide polymorphisms in colorectal cancer, and their effect sizes (from Tenesa and Dunlop7)
Gene/locus Chromosome SNP Effect size (odds ratio) Allele frequency Population attributable risk (%)
– 8q24 rs6983267 1⋅21 (1⋅15, 1⋅27) 0⋅51 9⋅7
GREM1 15q13 rs4779584 1⋅26 (1⋅19, 1⋅34) 0⋅18 4⋅5
SMAD7 18q21 rs4939827 1⋅18 (1⋅12, 1⋅23) 0⋅52 8⋅6
– 11q23 rs3802842 1⋅12 (1⋅07, 1⋅17) 0⋅29 3⋅4
EIF3H 8q23 rs16892766 1⋅25 (1⋅19, 1⋅32) 0⋅07 1⋅7
– 10p14 rs10795668 1⋅12 (1⋅10, 1⋅16) 0⋅67 7⋅4
BMP4 14q21 rs4444235 1⋅11 (1⋅08, 1⋅15) 0⋅46 4⋅8
CDH1 16q22 rs9929218 1⋅10 (1⋅06, 1⋅12) 0⋅71 6⋅6
RHPN2 19q13 rs10411210 1⋅15 (1⋅10, 1⋅20) 0⋅90 11⋅9
BMP2 20q12 rs961253 1⋅12 (1⋅08, 1⋅16) 0⋅35 4⋅0
Values in parentheses are 95 per cent c.i. SNP, single-nucleotide polymorphism.
and Dunlop7), inheritance of multiple SNPs (more than
10) confers a cumulative threefold risk of cancer. Other
successes from the GWAS/NGS approach have been iden-
tification of the GREM-associated duplication in heredi-
tary mixed polyposis syndrome8 andmutations in theDNA
polymerase genes POLE and POLD as a cause of hereditary
polyposis9. Identification of these mutations allows familial
testing, enhanced surveillance and reduction in the risk of
developing colorectal cancer.
In Crohn’s disease, multiple large-population GWAS
studies10 have been undertaken identifying multiple SNPs
of predisposition, suggesting that Crohn’s disease has a
strong heritable component. In total, more than 73 SNPs
have been identified, with the strongest association in the
NOD2 gene, which plays an important role in immunity. In
total, these loci make up about 20 per cent of the observed
inheritability of Crohn’s disease.
Comparatively less research has been undertaken in
germline susceptibility to ulcerative colitis; several large
population GWAS studies11–13 have demonstrated over 30
associated SNPs. These SNPs are in a variety of genes,
but are associated predominantly with immune system and
immunity-related genes. In addition, approximately 50 per
cent of identified loci overlap with those of Crohn’s disease.
Genomic analysis of colorectal cancer
The colorectal cancer TCGA project14 has carried out
exome sequencing (sequencing of the protein coding
regions of the genome), RNA-seq, genome-wide methyla-
tion analysis and protein expression (via reverse-phase pro-
tein arrays; RPPAs) of, at the time of writing, 461 colorectal
tumours. This group has confirmed recurrent driver muta-
tions in APC, TP53, SMAD4, PIK3CA and KRAS, but
also found novel therapeutic targets in ARID1A, SOX9
and FAM123B. Another study15 observed gene fusions
(merging of two genes, which causes abnormal function)
in R-spondin. The mutations observed in ARID1A are
Table 2 The Colorectal Cancer Subtyping Consortium
classification of colorectal cancer
Classifier Frequency (%) Characteristics
CMS1 14 MSI, immune pathway
activation/expression, right-side
tumours, older age at diagnosis,
females, hypermutation, BRAF
mutation, intermediate survival
CMS2 41 High CIN, MSS, strong Wnt/Myc
pathway activation, left-side
tumours, TP53 mutation, EGFR
amplification/overexpression, better
survival
CMS3 8 Low CIN, moderate Wnt/Myc pathway
activation, KRAS mutation, PIK3CA
mutation, IGFBP2 overexpression,
intermediate survival
CMS4 20 CIN/MSI heterogeneous,
mesenchymal/TGF-β activation,
younger age at diagnosis,
NOTCH3/VEGFR2 overexpression,
worse survival
CMS, Colorectal cancer Molecular Subtype; MSI, microsatellite
instability; CIN, chromosomal instability; MSS, microsatellite stable;
TGF, transforming growth factor.
particularly exciting as they present a potential therapeutic
target16. These data sets provide a wealth of information
about colorectal cancer, and linkage to a clinical data set
provides opportunities for future biomarker studies.
Recent work has examined the role of integration of mul-
tiple ’omics data sets to produce classifiers of disease17, also
known as endotypes. These are based on mutation, expres-
sion and immunological data sets. The Colorectal Cancer
Subtyping Consortium found four distinct Colorectal
cancer Molecular Subtypes (CMSs) (Table 2). The clas-
sifiers identified provide insight into the biology of the
distinct types. CMS1 consisted of microsatellite-unstable,
immunologically active tumours occurring mainly on
the right side in the elderly, whereas CMS2 (the most
frequent endotype) consisted of chromosomally unstable,
microsatellite-stable tumours. Further study of these
© 2015 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2015; 102: e29–e40
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classifiers may permit finer stratification, allowing precisely
targeted therapy.
Screening biomarkers
A wide variety of biomarkers have been examined18 in
colorectal cancer, as both markers of screening and of
prognosis. The ideal biomarker would be easily detectable
in either stool or blood, cheap and highly accurate.
Unfortunately, no current biomarker fits these criteria
precisely owing to the molecular heterogeneity associated
with colorectal cancer. The most promising markers seem
to be associated with abnormal DNA methylation. For
example, in colorectal cancer, differential methylation of
the septin 9 gene has been shown to have 72 per cent
sensitivity and 90 per cent specificity for the detection of
malignancy. However, many biomarker studies across all
cancer types are plagued by poor study design, insuffi-
cient power and non-hypothesis-driven marker selection.
Currently, a well designed, UK-based trial of methylated
biomarkers, the ENDCaP-C study (Enhanced Neoplasia
Detection and Cancer Prevention in Chronic Colitis)
is under way19, examining their value in the detection
of dysplasia in a screened population of patients with
ulcerative colitis.
Another rich field of developing interest in colorectal
cancer is sequencing of the microbial genomes that exist
within the colon. Experimental murine models seem to
indicate that the microbiome within the colon alters the
risk of colorectal cancer by modulating inflammation20.
This has also been demonstrated to be the case in patients
with inflammatory bowel disease, for both ulcerative colitis
and Crohn’s disease21.
Metabolomic techniques also show promise in acting as
screening biomarkers. Mirnezami and co-workers22 under-
took high-resolution magic-angle spinning nuclear mag-
netic resonance spectroscopy in 44 tumour–normal pairs,
finding cancer-specific metabolite patterns allowing differ-
entiation of cancer from normal tissues, in addition to find-
ing changes in the metabolome as the tumour progressed.
A number of proteomic studies have also been carried out
in colorectal cancer23, although these all suffer from lack of
validation, and the variety of different markers identified
undoubtedly reflects the varying populations from which
they were sampled.
Targeted therapies, prognostic and predictive
biomarkers
The discovery that the epidermal growth factor (EGF)
pathway in colorectal cancer was sensitive to inhibition by
anti-EGF receptor (EGFR) monoclonal antibodies (mAbs)
led to the rapid development of panitumumab and cetux-
imab. However, it was found in initial trials that the
antibodies seemed to have no clinical effect against col-
orectal cancer; although a proportion of patients seemed
to benefit from therapy, the majority did not24. It was
found subsequently that mutations in the EGFR path-
way genes (KRAS, BRAF, NRAS and PIK3CA) conferred
resistance to anti-EGFR mAbs due to hyperactivation of
the pathway independent of the EGFR25. The CRYSTAL
trial26 compared patients with a KRAS mutation and those
without, finding a clear response and survival benefit for
anti-EGFR mAbs in patients without mutation. A num-
ber of other pathway-specific inhibitors exist for colorectal
cancer, including the antivascular endothelial growth fac-
tor (VEGF) mAb bevacizumab, MEK inhibitors that tar-
get EGF pathway mutated cancers and cancer vaccines.
The FOCUS4 trial27 is currently recruiting patients for a
molecularly stratified trial of metastatic colorectal cancer
therapy: patients are selected for a specific therapy when
they possess a mutation specific to that cancer. This raises
the intriguing possibility of molecular-targeted therapy for
primary, non-metastatic tumours as neoadjuvant therapy
before surgery.
A commercially available test exists for prediction of
recurrence and benefit for 5-fluorouracil chemother-
apy (Oncotype DX®; Genomic Health, Redwood
City, California, USA), based on a multigene panel of
RNA expression from formalin-fixed paraffin-embedded
tissues28. This was developed by screening 761 candidate
genes against a large cohort of 1851 patients undergoing
surgery for colorectal cancer, with or without adjuvant
5-fluorouracil therapy. Validation was carried out on the
QUASAR study29, which could stratify prognosis, but did
not correlate with benefit from chemotherapy.
Another intriguing possibility is the use of immune-based
stratification to estimate colorectal cancer prognosis. Lal
et al.30 used the TCGA expression data set to identify
four different immune classifiers based on the expres-
sion of immune system-related genes. Immunogenicity is
thought to be related to survival, as tumours that are
more visible to the immune system are more likely to
undergo destruction by the immune system. One of the
mechanisms that may occur in highly mutated tumours,
such as tumours with a POLE mutation or those with
microsatellite instability, is where the large number of
mutations causes a variety of frameshift mutations. These
frameshift mutations drive the production of neoantigens31
caused by the alternative splicing of multiple genes, which
increases the visibility of the tumour to the immune
system.
© 2015 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2015; 102: e29–e40
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Upper gastrointestinal tract: oesophagogastric
cancer
Genetic predisposition
Research into predisposition to gastro-oesophageal cancer
is complicated by the fact that it can arise in two histolog-
ically different epithelial types: squamous cell carcinoma
(SCC) and adenocarcinoma. A significant proportion of the
risk is likely to comprise lifestyle factors such as smoking,
gastro-oesophageal reflux and diet.
In adenocarcinoma, a GWAS of the premalignant stage
of oesophageal cancer32, Barrett’s oesophagus, demon-
strated associations between the major histocompatibility
locus and a gene associated with oesophageal development
(FOXF1). It was also found that the predisposition to Bar-
rett’s oesophagus was made up of multiple common vari-
ants of small effect, rather than a single genetic driver. A
further GWAS of oesophageal adenocarcinoma32 demon-
strated associations with transcription factors (CRTC1,
FOXP1, BARX1). In light of these results it is difficult to
highlight SNPs that may act as markers for increased dis-
ease risk or act as molecular targets for therapy.
Several GWAS studies have been undertaken, predomi-
nantly in Chinese populations at high risk of oesophageal
SCC33,34. They highlighted SNPs in the riboflavin trans-
porter C20orf54, and a cell growth and differentiation
gene, PLCE1. Riboflavin deficiency was identified before
this study as a risk factor35 for oesophageal SCC. The
PLCE1 variant was further found to interact specifically
with tobacco smoke exposure36.
Genomic analysis of oesophagogastric cancer
Both the Broad Institute (Cambridge, Massachusetts,
USA) and the OCCAMS (Oesophageal Cancer Clinical
and Molecular Stratification) Consortium have stud-
ied oesophageal adenocarcinoma. The Broad Institute
project37 undertook whole-exome and whole-genome
sequencing in 149 tumour–normal pairs, verifying previ-
ously identified mutations in TP53, CDKN2A, SMAD4,
ARID1A and PIK3CA. Previously unidentified mutations
in SPG20, TLR4, ELMO1 and DOCK2 were also found,
and a possible role for the RAC1 pathway (a modulator of
epithelial–mesenchymal transition) was identified.
The OCCAMS Consortium38 examined whole-genome
sequencing of oesophageal adenocarcinoma, as well as tar-
geted sequencing of never-dysplastic Barrett’s oesophagus
(which did not progress to malignancy) and high-grade
dysplasia. They found that TP53 was the dominant muta-
tion seen in adenocarcinoma, in over 80 per cent of
samples, but that these mutations were also present in
biopsies from never-dysplastic patients, contrary to what
was expected based on the known oncological progression
of these lesions. The only stage-specific mutations seen in
high-grade dysplasia and adenocarcinoma were in TP53
and SMAD4.
Whole-genome and whole-exome sequencing of
oesophageal SCC has also been performed39. Whole-
genome sequencing of 17 tumour–normal pairs and
whole-exome sequencing in a further 71 tumour–normal
pairs identified recurrent mutations in TP53, RB1,
CDKN2A, PIK3CA, NOTCH1 and NFE2L2, as well as
ADAM29 and FAM135B. The genomic landscape of
oesophageal SCC was significantly different from that of
oesophageal adenocarcinoma, highlighting the different
therapeutic strategies that are needed in this disease.
Biomarkers of predisposition/sensitivity
and screening
Given the above OCCAMS findings, it is difficult to use
TP53 mutation as a biomarker of adenocarcinoma, as it
has also been identified in biopsies from never-dysplastic
patients, who should not progress to adenocarcinoma. As
a precursor to the OCCAMS study38, the same group
undertook combined-array CGH (comparative genomic
hybridization, a type of microarray analysis looking at
chromosomal abnormalities) in tumour samples and gene
expression via microarray40. They found a pattern of
copy number alterations and associated expression change
that could identify poor-prognosis oesophageal adenocar-
cinoma. The OCCAMS group also examined gene expres-
sion changes in adenocarcinoma using RNAmicroarrays41,
finding a four-gene expression panel of DCK , PAPSS2,
SIRT2 and TRIM44 that were independently predictive of
survival.
There have been a number of attempts at developing
methylated biomarkers in oesophageal adenocarcinoma,
both as screening biomarkers and to identify high-risk Bar-
rett’s oesophagus. The genes studied include CDKN2A,
vimentin, P14ARF, CDX2, SOCS1/3, SFRP1/2/4/5 and
WIF142–44. Unfortunately no consistent marker can be
identified that successfully differentiates adenocarcinoma
from normal oesophagus and high-grade Barrett’s dyspla-
sia. These types of focused biomarker will become increas-
ingly important to stratify therapy.
Attempts have been made using proteomics45 to dis-
tinguish oesophagogastric cancer from benign disease, to
allow screening. MALDI mass spectrometry was used to
compare the differences between oesophageal cancer and
normal mucosa, and gastric cancer and normal mucosa.
It was found that, although there were clear differences
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between cancer and normal tissue, there was a wide variety
of changes that varied between different tumours, making
determination of a specific biomarker difficult.
Targeted therapies
Despite the recent advances in discovery science in
gastro-oesophageal cancer, few therapeutic targets cur-
rently exist. A small proportion of cancers overexpress the
human EGFR 2 (HER2) protein46, and clinical trials of
trastuzumab, a mAb against the HER–receptor complex
are ongoing. The ToGA (Trastuzumab for Gastric Can-
cer) study47 investigated the addition of trastuzumab to
standard chemotherapy, and demonstrated a small survival
benefit in HER2-positive cancer. Targeting by anti-VEGF
therapy is also undergoing clinical trials48; however, results
have been mixed with no improvement in overall survival,
but improvements in response rates and progression-free
survival.
Breast cancer
Genetic predisposition
The role of inherited variability in breast cancer has
been investigated extensively. A very strong signal for
variants in the fibroblast growth factor receptor 2 gene
(FGFR2) have been found in GWAS studies across mul-
tiple populations49–51. Carriers of the two low-risk alleles
at FGFR2 (frequency 38 per cent of the population) have a
relative risk of breast cancer of 0⋅83 comparedwith the gen-
eral population52; carriers of one high-risk and one low-risk
allele (47 per cent) have a relative risk of 1⋅05; and car-
riers of two high-risk alleles (14 per cent) have a relative
risk of 1⋅2653. FGFR2 mutations are of particular inter-
est as they may represent a therapeutic target in breast
cancer54.
A recent GWAS55 in oestrogen receptor (ER)-negative
breast cancer demonstrated four variants that reached
genome-wide significance in MDM4, LGR6, FTO and a
SNP within the 2p24⋅1 region. These SNPs were present
only in ER-negative breast cancers, in contrast to the find-
ings in a combined ER-positive/ER-negative GWAS56.
This found variants located with PTHLH, known to have
a role in breast development, and NRIP1, a co-factor of
the ER.
Next-generation sequencing
A number of NGS projects have examined the muta-
tion spectrum in breast cancer. The most comprehensive
of these is from the TCGA project57, which carried out
exome sequencing, RNA-seq, methylation array analysis
and RPPA of 463 patients. Recurrentmutations were found
in TP53, PIK3CA and GATA3 at frequencies of over 10 per
cent, reinforcing their role as driver mutations in breast
cancer, as well as mutations in several dozen genes pre-
viously identified in breast cancer. Study of the role of
expression subtypes in breast cancer demonstrated four
separate subtypes (luminal A/B, basal and HER2E), with
the mutational burden and spectrum varying in each. The
HER2E subtype demonstrated a relatively low mutational
frequency, whereas the luminal A subtype demonstrated
large numbers of significantly mutated genes, the most fre-
quent mutation being in PIK3CA.
In common with colorectal cancer, methylation array
analysis of breast cancer revealed a hypermethylator phe-
notype, associated with the luminal B expression subtype,
and a hypomethylated phenotype associated with a basal
expression subtype and comparatively higher frequency of
TP53mutation. Copy number analysis was also performed,
with the previously identified amplifications in HER2 and
EGFR being identified, as well as novel amplifications in
PIK3CA and FOXA1 and deletions in RB1 and PTEN .
A striking finding throughout the study was the detection
of genetic heterogeneity both within tumours and between
samples, highlighting the diverse nature of this disease.
Shah and colleagues58 examined the mutational spec-
trum in triple-negative breast cancer (ER/progesterone
receptor/HER-negative), again finding that TP53 and
PIK3CA mutations were clonally dominant, but also find-
ing a wide variety of mutation spectra, including tumours
with few driving mutations and tumours with extremely
complex mutational spectra (the hypermutated pheno-
type). A separate study59 identified recurrent mutations in
the transcription factor genes CBFB and RUNX1, as well
as a gene fusion seen only in triple-negative breast cancers,
the MAGI3–AKT3 fusion transcript. An exome sequenc-
ing study60 of 100 breast cancers at the Wellcome Trust
Sanger Institute (Cambridge, UK) identified more than 40
driver mutations in a breast cancer cohort, including genes
now known to be important therapeutic targets, such as
AKT1/2, ARID1B, CASP8 andMAP3K1.
NGS also has applications in the monitoring of
metastatic disease or in recurrence. Dawson et al.61
used a combination of targeted NGS, digital PCR and
whole-genome sequencing to examine DNA circulating
in the bloodstream that is shed from metastatic tumours.
They found that increasing amounts of circulating DNA
correlated with poorer overall survival, but also that,
by comparing mutations in the primary tumour with the
cell-free DNA obtained, recurrence of the primary tumour
could be detected by the presence of the same somatic
© 2015 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2015; 102: e29–e40
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mutations in the circulating DNA. This technology has
applications for the detection of recurrence in multiple
tumour types across the disease spectrum.
Biomarkers of predisposition/sensitivity
and screening
One-step nucleic acid amplification (OSNA) is an example
of the use of genetic technologies to stratify patients. It
works by the detection of raised copy number of the cytok-
eratin 19 gene (CK19) as a surrogate marker of the presence
of breast cancer within sentinel lymph nodes62, and is used
as a proxy marker for axillary lymph node positivity in
breast cancer. OSNA has been approved as a technolog-
ical solution to determine sentinel lymph node positivity
by the UK National Institute for Health and Care Excel-
lence (NICE), and has been shown to be equivalent to
both radioisotope- and dye-based technologies for map-
ping lymph nodes63.
Another recent development is the DNA dam-
age response assay for the prediction of response to
anthracycline/cyclophosphamide-based chemotherapy in
breast cancer64. The study examined RNA expression
in patients with a DNA damage response deficiency and
developed a 44-gene RNA expression panel that could pre-
dict response to chemotherapy in sporadic breast cancer.
Targeted therapies
A rich variety of targeted therapies exist for breast can-
cer, based on the underlying biology of the tumour, gained
by the extensive molecular research carried out on breast
cancer. Aromatase inhibitors (such as anastrazole) and tar-
geted ER modulators (such as tamoxifen) have been used
extensively for many years, based on the observation that
a proportion of breast cancers are ER-positive. Identifi-
cation of the overexpression of HER2 in breast cancer
has allowed targeting with both mAbs (trastuzumab) and
small-molecule tyrosine kinase inhibitors such as lapatanib,
with appreciable survival benefits.
More recently, several novel pathways have been
identified as being dysregulated in breast cancer:
the insulin-like growth factor (IGF) 1 pathway; the
BRCA-associated double-strand break repair pro-
tein, poly(ADP-ribose) polymerase (PARP) 1; and the
phosphatidylinositol-3-kinase (PIK3)–Akt–mammalian
target of rapamycin (mTOR) pathway. Immunohisto-
chemistry of IGF-1 has revealed that it is overexpressed
in more than 50 per cent of breast cancers, and a mAb
(cixutumumab) that targets these pathways is currently in
phase 1 studies65.
PARP inhibitors were identified from work targeting
BRCA mutant breast cancer66 as a therapeutic strategy to
treat patients with BRCA mutations. A small molecular
PARP inhibitor, olaparib, has been used to treat germline
BRCA mutant breast cancer67, with a clinical trial (the
OlympiAD trial) currently under way. PARP inhibitors
also show promise in triple-negative breast cancer, as
studies have shown that a proportion of these women
possess BRCA mutations68,69 and may respond to PARP
inhibitors. mTOR pathway inhibitors, such as everolimus,
should theoretically be of benefit in breast cancer as a
result of the dysregulation of this pathway demonstrated
by molecular studies, although initial results have been
disappointing70.
The future
The union of basic biological research with surgery
has allowed the field of translational surgical biology
to develop, utilizing modern molecular technologies to
stratify surgical disease based on therapeutic and outcome
response.
A number of possibilities exist for future research.
First, whole-genome studies using NGS technologies of
prospectively collected samples will allow identification
of biomarkers for response (such as radiotherapy in rectal
cancer) and treatment (for instance, molecularly targeted
therapies). An example of current clinical issues that could
be answered using this technology is the response of
rectal cancer to radiotherapy. Around 5–10 per cent of
patients with advanced rectal cancer given preoperative
radiotherapy have a complete response71. Research is cur-
rently under way to understand what makes these tumours
particularly sensitive (the so-called extreme responders) to
radiation, and it is likely that a highly focused approach
using NGS will identify responsible pathways.
Stratification of premalignant lesions is also an important
focus of research. In colorectal, upperGI and breast cancer,
few biomarkers exist to predict which premalignant lesions
will progress to invasive cancer. Typically less than 1 per
cent of patients with Barrett’s oesophagus will progress
to invasive oesophageal cancer, but no markers reliably
predict this. The use of retrospective cohorts of patients
with progressive Barrett’s oesophagus and NGS analysis
might identify genetic markers.
The concept of disease classifiers will play an increas-
ingly important role and, as more NGS data sets become
available, the granularity of classifiers will improve to
the extent whereby a more precise understanding of the
biology underlying a tumour will be available. This will
be enhanced by the integration of multiplatform (NGS,
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metabolomics, proteomics) data into these classifiers, and
will allow tailoring of therapy to the underlying disease.
The availability of NGS data sets for the surgical
population will be enhanced by the commissioning
of the UK 100 000 Genomes Project72. This exciting
project will carry out whole-genome sequencing of 50 000
tumour–normal pairs from patients with a range of can-
cers, but concentrating primarily on colorectal, breast,
lung and prostate cancer. The data made available by this
project will allow a highly detailed examination of the
drivers in these cancer types; this is the largest project of
its type in the world.
Although the technological advances are numerous, they
are not without their own challenges. The recent iden-
tification of intratumoral heterogeneity, long hypothe-
sized but only recently identified definitively in renal cell
cancer73 and in preneoplastic lesions74, provides unique
challenges for stratification. It is likely that multiple sub-
clones of tumour exist within a primary tumour, each with
differing characteristics. These will dictate prognosis and
response to therapy, and further investigation is needed
to understand the extent and consequences of this phe-
nomenon.
Technological leaps in molecular biology will enable
selection of the right therapy for the right patient at the
right time, and further build on the surgical and anaesthetic
improvements achieved in the past century to provide
maximal benefit for the patient.
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